Articles Vol. 65 No. CĐ10 - Bệnh viện Thống Nhất 30/10/2024

11. INVESTIGATING THE STATUS OF HOSPITAL-ACQUIRED PNEUMONIA AND ANTIBIOTIC USAGE IN THE TREATMENT OF HOSPITAL-ACQUIRED PNEUMONIA AT THONG NHAT HOSPITAL

Le Van Lam1,2, Vo Thi Hoa1,2, Nguyen Thi Ngoc Thuy1,2, Ha Le Viet Dung1,2, Ho Quoc Cuong1,2, Tran Thi Phuong Mai1,2, Bui Thi Huong Quynh1,2, Pham Thi Thu Hien1,2
1 Thong Nhat Hospital
2 Bệnh viện Thống Nhất
Corresponding author: levanlam20101987@gmail.com
DOI: 10.52163/yhc.v65iCD10.1596
62 Views
25 Downloads
Keywords
Hospital-acquired pneumonia (VPBV) antibiotics
Abstract

Objective: The study aimed to assess the prevalence of Hospital-acquired pneumonia (HAP) and analyze the antibiotic usage in treating HAP at Thong Nhat Hospital.

Subjects and Methods: A cross-sectional study was conducted, retrieving data from the medical records of inpatients treated at Thong Nhat Hospital in August 2023. Screening of medical records met the diagnostic criteria for HAP, including patients diagnosed with HAP by physicians or those diagnosed with pneumonia after at least 48 hours of hospitalization (satisfying the diagnostic criteria outlined in the 2016 Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) guidelines on the management of HAP and ventilator-associated pneumonia). A comparison of various indices, including treatment duration, medication costs, and antibiotic usage costs, was conducted between patient groups with and without HAP. Microbial analysis, antibiotic usage, and defined daily doses (DDD)/100 days of treatment were examined in patients with HAP.

Results: The results from 2855 medical records revealed that there were 208 cases of HAP, accounting for 7.29%. The average age of patients with HAP was 72.65 years, with a male gender ratio of 55.77%. Patients with HAP had an extended treatment duration of approximately 7.35 days, resulting in a 2.7 times increase in treatment costs, a 10 times increase in medication costs, and a 25 times increase in antibiotic costs compared to patients without HAP. The mortality/severity rate in the healthcare-associated infection group was significantly higher compared to without HAP (22 times). The primary causative agents of HAP were Gram-negative bacteria, constituting 71.25%, including Klebsiella pneumonia (22.82%), Escherichia coli (16.78%), Pseudomonas aeruginosa (11.41%), and Acinetobacter baumannii (9.4%). Gram-positive bacteria accounted for 18.79%, with Staphylococcus being the highest at 16.78%. Fungi were also identified as causative agents, with a prevalence of 10.06%. The main antibiotics used for treatment were antibiotics group I, representing 50.33% of the total DDD per 100 days of treatment and constituting 80.88% of the antibiotic treatment costs.

Conclusion: HAP is one of the common hospital-acquired infections. Patients with HAP often experience prolonged hospital stays, leading to increased treatment costs, decreased treatment effectiveness, and reduced quality of healthcare.

References
[1]
Nguyễn Thanh Bảo, Cao Minh Nga, Trần Thị Thanh Nga, Vũ Thị Kim Cương, Nguyễn Sử Minh Tuyết, Vũ Bảo Châu, Huỳnh Minh Tuấn (2012), “Chọn lựa kháng sinh ban đầu trong điều trị nhiễm khuẩn bệnh viện tại một số bệnh viện TP HCM”, Y học TP HCM, tập 16, phụ bản số 1. Google Scholar
[2]
Nguyễn Việt Hùng (2019), “Phân tích thực trạng tiêu thụ kháng sinh và sử dụng kháng sinh trong viêm phổi bệnh viện tại Bệnh viện Đa khoa tỉnh Điện Biên”, Luận văn thạc sĩ Dược học, Đại học Dược Hà Nội Google Scholar
[3]
Nguyễn Thành Nghiêm, Phạm Thành Suôl (2022), “Mô tả đặc điểm vi khuẩn và tình hình đề kháng kháng sinh của vi khuẩn trên bệnh nhân viêm phổi bệnh viện tại Bệnh viện Đa khoa thành phố Cần Thơ”, Tạp chí Y học Cần Thơ, số 51/2022 Google Scholar
[4]
American Thoracic Society and Infectious Diseases Society of America, (2005). “Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia”. American journal of respiratory and critical care medicine, 171(4), p.388 Google Scholar
[5]
Carl Suetens, et al (2018), “Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017’’, Article submitted on 20 Sep 2018. Google Scholar
[6]
Centers for Disease Control and Prevention (1995). “Pneumonia and influenza death rates-- United States”, 1979-1994. MMWR. Morbidity Google Scholar
[7]
and mortality weekly report, 44(28), pp.535-537. Google Scholar
[8]
11 Dietrich, E.S., Demmler, M., Schulgen, G., Fekec, K., Mast, O., Pelz, K. and Daschner, F.D., (2002). “Nosocomial pneumonia: a cost-of-illness analysis”. Infection, 30, pp.61-67. Google Scholar
[9]
Falcone, M., Russo, A., Silverj, F.G., Marzorati, D., Bagarolo, R., Monti, M., Velleca, R., D'Angelo, R., Frustaglia, A., Zuccarelli, G.C. and Prina, R., (2018). “Predictors of mortality in nursing-home residents with pneumonia: a multicentre study”. Clinical microbiology and infection, 24(1), pp.72-77. Google Scholar
[10]
Houston MS, Silverstein MD, Suman VJ (1997). “Risk factors for 30-day mortalityin elderly patients with lower respiratory tract infection”. Arch Intern Med 1997; 157:2190–5. Google Scholar
[11]
Kalil, A.C., Metersky, M.L., Klompas, M., Muscedere, J., Sweeney, D.A., Palmer, L.B., Napolitano, L.M., O'Grady, N.P., Bartlett, J.G., Carratalà, J. and El Solh, A.A., (2016). “Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical Google Scholar
[12]
practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society”. Clinical infectious diseases, 63(5), pp. Google Scholar
[13]
e61-e111. Google Scholar
[14]
Kollef MH, Hamilton CW, Ernst FR (2012), “Economic impact of ventilator-associated pneumonia in a large matched cohort”. Infect Control Hosp Epidemiol 2012; 33:250. Google Scholar